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Activation of telomerase by human papillomavirus 16 (HPV16) E6 is a critical step for cell immortaliza-
tion and transformation in human foreskin keratinocytes (HFKs). Multiple transcription factors have
been identiﬁed as being involved in E6-induced hTERT expression. Here, we adapted an unbiased in vivo
screen using a LacO–LacI system in human cells to discover hTERT promoter-interacting regulators. This
approach allowed us to identify a novel hTERT repressor, Maz, which bound the hTERT promoter.
E6 expression reduced Maz binding and correspondingly increased Sp1 binding at the hTERT promoter.
Knockdown of Maz further increased histone acetylation, as well as hTERT expression in the presence of
E6. Overall, these data indicate the utility of a novel screen for promoter-interacting and transcription-
regulating proteins. These data also highlight multiple factors that normally regulate hTERT repression in
HFKs, and therefore are targeted by E6 for hTERT expression.
& 2013 Elsevier Inc. All rights reserved.Introduction
Linear chromosomes are capped with non-gene coding repetitive
DNA, and in normal somatic cells, this DNA is serially eroded with
each cellular division. Critically short, dysfunctional telomeres even-
tually induce cells to senesce or apoptose (Hayﬂick, 1965). hTERT, the
catalytic subunit of telomerase, is the rate-limiting component of
telomerase activity, which maintains telomere length to protect the
ends of chromosomes from degradation as well as preventing end-
to-end fusions (Blackburn, 2001). Germ cells and stem cells are able
to replicate indeﬁnitely due to constitutive expression of hTERT.
Cancer cells also utilize telomerase, by increasing telomerase activity,
to maintain telomere length. More than 85% of all cancer cells have
activated hTERT transcription (Hiyama and Hiyama, 2003).
Increased telomerase activity due to the activation of hTERT
expression has emerged as a hallmark of cancers, and hTERT tran-
scriptional regulation has been a focus of intense study in cancer
research. Researchers have been interested in cis and trans elements
that regulate hTERT expression as well as the chromatin structure of
the hTERT gene itself (Bryce et al., 2000; Cong et al., 1999; Wang and
Zhu, 2004). The hTERT gene is located at the end of chromosome ﬁvell rights reserved.
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y).
pinion, the ﬁrst two authorswithin a semi-heterochromatic region (Bryce et al., 2000) that is
nuclease-resistant (Wang and Zhu, 2004). Chromatin remodeling in
telomerase-negative cells has been shown to play an important role in
activation of hTERT expression (Hou et al., 2002; Takakura et al., 2001).
Inhibition of histone deacetylase activity relaxes the chromatin allow-
ing hTERT transcriptional activation (Hou et al., 2002; Wang and Zhu,
2004). Sequence analysis of the hTERT promoter revealed that the
hTERT promoter is GC-rich, lacks TATA and CAAT boxes, but contains
several binding sites for transcription factors, such as E-boxes for Myc
binding and Sp1 binding sites (Cong et al., 1999), all of which
facilitated identiﬁcation of candidate transcriptional regulators of
hTERT in tumor cells.
Studies have indicated that the regulation of hTERT expression is
multifactorial. Many proteins directly or indirectly regulate hTERT
transcription, including transcriptional repressors, such as p53, Mad,
Wt1, Mzf-2, Sip1 and Menin, as well as transcriptional activators, such
as Myc, Sp1 and Ets family transcription factors (Greenberg et al., 1999;
Horikawa and Barrett, 2003; Kyo et al., 2000; Li et al., 2002; Lin and
Elledge, 2003; Maida et al., 2002; Racek et al., 2005). Therefore, there
is no single factor utilized in oncogenic induction of hTERT expression,
and chromatin remodeling plays an additional, critical role in tran-
scriptional regulation.
Human tumor viruses have evolved multiple strategies to promote
telomerase activation and maintain telomere length. High risk (HR)
HPV16 oncoprotein E6 (E6) contributes to keratinocyte immortaliza-
tion and carcinogenesis through activation of telomerase, primarily
through trans-activation of hTERT (Fu et al., 2003; Gabet et al., 2008;
M. Xu et al. / Virology 446 (2013) 17–2418Gewin et al., 2004; Oh et al., 2001; Xu et al., 2008). We and others have
shown that E6 interacts with Myc on the hTERT promoter to increase
its expression (Gewin and Galloway, 2001; Veldman et al., 2003), and
E6 modiﬁes the chromatin structure of the hTERT promoter through
histone acetylation and dimethylation, dependent on the endogenous
E6-Associated cellular Protein (E6AP) (Bedard et al., 2008; James et al.,
2006; Liu et al., 2005; Xu et al., 2008). Our group identiﬁed a novel
constitutive hTERT repressor, NFX1-91, which interacts with the
mSin3A-histone deacetylase complex (HDAC) at the hTERT promoter
and maintains the gene in a repressed state. E6 interacts with E6AP
and targets NFX1-91 for proteasome-mediated degradation, removing
the inhibitory histone deacetylase complex and allowing the activation
of hTERT expression (Gewin et al., 2004; Xu et al., 2008). Knockdown
of NFX1-91 is able to induce hTERT transcription, as well as chromatin
modiﬁcation at the hTERT promoter (Gewin et al., 2004; Xu et al.,
2008). Therefore, E6 affects hTERT and increases telomerase activity
through transcription factor interactions, transcription repressor degra-
dation, and chromatin structure modiﬁcations.
However, many unanswered questions about E6-induced hTERT
expression remain. In examining cis elements in the hTERT promoter,
we and others found that both E-boxes and Sp1 binding sites at the
hTERT promoter play important roles in E6-induced hTERT expres-
sion in keratinocytes (Cheng et al., 2008; Gewin and Galloway, 2001;
Oh et al., 2001; Xu et al., 2008). We have consistently detected Myc
binding to the hTERT promoter in both HFK and E6 expressing cells
without changes to the total Myc protein levels (Gewin and
Galloway, 2001; Xu et al., 2008). Therefore, the underlying mechan-
ism of E6-induced hTERT expression remained unclear.
Many recent studies have focused on testing and conﬁrming
hTERT promoter interacting transcription factors through analysis of
the required cis elements in the hTERT promoter in vitro. However,
modulations of protein and DNA elements used for these in vitro
assays do not allow study of as-of-yet unknown factors that co-
regulate hTERT expression. Therefore, we took an unbiased approach
to identify proteins that bind to the hTERT core promoter in humanFig. 1. Characterization of the LacO–LacI system in 293 TT cells: (A) schematic diagram of t
plasmid containing LacO repeats were captured by LacI-Flag afﬁnity puriﬁcation. (B) V
pYLacO, and LacI-Flag cotransfected with pYLacO–hTERTp by MS analysis.cells in vivo using a LacO–LacI system. This screen has been
successfully used in yeast to identify speciﬁc DNA interacting proteins
(Akiyoshi et al., 2009). We adapted this system for human cells and
using this approach, we not only conﬁrmed previously identiﬁed
hTERT transcriptional regulators, such as Myc/Max and Sp1, but we
revealed two new proteins bound to the hTERT promoter, Foxc1 and
Maz, that by functional siRNA screen regulated hTERT expression.
Foxc1 is a member of the superfamily of forkhead transcription
factors, and has been shown to play roles in multiple developmental
processes (Birkenkamp and Coffer, 2003; Coffer and Burgering,
2004). Maz functions as a transcription factor (Himeda et al., 2008;
Tsutsui et al., 1999), and studies have shown that Maz regulates gene
expression through binding to the GC-rich elements, which are
similar to the hTERT promoter Sp1 binding sites (Song et al., 2003).
We found opposing binding of Sp1 and Maz on the hTERT promoter,
with the switch mediated by E6. All of these proteins directly affected
the chromatin structure of the hTERT promoter through histone
acetylation and therefore affect hTERT expression.
These studies highlight a new non-biased protocol to screen for
DNA binding proteins found at a gene promoter using mammalian
cells. Using this screen, we identiﬁed proteins known to bind to our
promoter of interest, hTERT, and new transcriptional regulators that
affect hTERT expression through chromatin remodeling in E6 expres-
sing keratinocytes. These data support that hTERT repression is
multilayered, and multiple factors are targeted for regulation by E6
in HPV-associated disease and cancers to drive telomerase activity and
oncogenic progression.Results
Characterization of the LacO–LacI system in mammalian cells
The majority of studies on regulation of hTERT expression have
focused on testing putative transcription factors that likely boundhe LacO–LacI system adapted in 293 TT cells. Proteins bound to the pYLacO–hTERTp
enn diagram of proteins identiﬁed in LacI-Flag only, LacI-Flag cotransfected with
Table 1
hTERT regulators identiﬁed by small RNA interference.
Gene symbol Gene ID siRNA #1a siRNA #2a
Myc NM_002467  
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contrast, we adapted a LacO–LacI system initially developed in
yeast to identify hTERT transcription regulators in human cells
(Fig. 1A). To overcome the low copy number of transfected
plasmids in mammalian cells, pYLacO was constructed to contain
the SV40 origin and three copies of the LacO sequence. The SV40
origin drives plasmid replication under the regulation of large T
antigen expressed by 293 TT; approximately 500 copies of the
plasmid per cell 24 h after transfection, and 2000 copies per cell
48 h after transfection, were detected using these plasmid mod-
iﬁcations (data not shown). The core 787 base pair (bp) hTERT
promoter (725 bp to +61 bp) was inserted into pYLacO to give
the pYLacO–hTERTp plasmid. With the SV40 origin driving plas-
mid ampliﬁcation, there was a signiﬁcant increase in the number
of hTERT promoter sites to which factors could bind. pYLacO–
hTERTp and the Flag-tagged LacI (LacI-Flag) construct were co-
transfected into 293 TT cells. This allowed the LacI-Flag protein to
bind to the three LacO elements in pYLacO–hTERTp. Immunopre-
cipitation by anti-Flag antibody then pulled down the expressed
LacI-Flag, its interacting plasmid pYLacO–hTERTp, and endogenous
293 TT proteins bound to the pYLacO–hTERTp. Proteins were
identiﬁed by Mass Spectrometry (MS) analysis (Fig. 1A).
Two controls were used in this experiment in parallel: ﬁrst, cells
were transfected with LacI-Flag only, to exclude proteins bound to
the LacI-Flag protein, the anti-Flag antibody or to the beads. Second,
cells were co-transfected with LacI-Flag and pYlacO (lacking the
hTERT promoter), to identify proteins that bound to non-hTERT
sequences such as the SV40 promoter. Stringent ﬁlter parameters and
at least two unique peptides were required to identify a given protein
by MS analysis. Twenty-two proteins were identiﬁed in all three
experimental samples, indicating that they may be non-speciﬁcally
bound (Fig. 1B). Fifty proteins were identiﬁed in both pYLacO and
pYLacO-hTERTp samples (Fig. 1B); these proteins could be bound to
sequences common to the pYLacO backbone, or to both the backbone
and the hTERT promoter. Thirty-ﬁve proteins were found to be
unique in the pYLacO-hTERTp sample (Fig. 1B). Complete lists of
these proteins are shown in the Supplementary Tables S1 and S2.Sp1 NM_138473  
Maz NM_002383 +++ +
Foxc1 NM_001453 ++ +
Control (Luciferase) x65324 NC NC
a hTERT mRNA level: +: up more than 1.75-fold; ++: up more than three-fold;
+++: up more than six-fold; : down more than 1.75 fold; : down more than
three-fold; NC—no change.Conﬁrmation of putative hTERT regulator in HFKs
Although 293 TT cells were used for the LacO–LacI screen to
identify hTERT promoter-binding proteins in mammalian cells as 293
TT cells could amplify the copy number of the transfected plasmid upFig. 2. E6 altered the binding of Maz and Sp1 at the hTERT promoter in HFKs without chang
Maz and Sp1 in HFKs (Loss of p53 expression used as an indicator of E6 expression, and
promoter in HFKs, and Sp1was enriched at the hTERT promoter in E6-HFKs. (β-globin us
from two independent experiments.).to 2000-fold per cells, we were interested in the regulation of hTERT
expression in HFK cells and speciﬁcally in E6-expressing HFK cells.
Of the 85 proteins identiﬁed as bound to the pYLacO–hTERTp and/or
pYLacO backbone plasmid in 293 TT cells (Supplementary Table 1),
21 proteins with known transcriptional activity were chosen for
further screening in HFKs. Each was tested as a potential regulator of
hTERT expression in HFK cells with and without E6 by a siRNA
screen, with two independent siRNAs targeting each individual genes
for knock down. Four proteins showed consistent effects on hTERT
expression in E6 HFKs when they were knocked down, as shown in
Table 1. Myc and Sp1 were conﬁrmed by siRNA as transcriptional
activators of hTERT in E6 HFKs, and two novel hTERT repressors were
found in the LacO–LacI screen, Maz and FoxC1, (Table 1).
E6 expression regulated Maz and Sp1 binding at the hTERT promoter
Sp1, a known transcriptional regulator of hTERT in E6 expres-
sing cells (Kyo et al., 2000; Pang et al., 2002), was conﬁrmed in the
LacO–LacI screen. As the SV40 regulatory region contains GC-rich
Sp1 binding sites, and Sp1 has also been shown to bind the SV40
early promoter (Dynan et al., 1985; Dynan and Tjian, 1983), we
were encouraged that Sp1 was found in both pYLacO–hTERTp and
pYLacO samples (Table S1). Maz was also identiﬁed in the LacO–
LacI screen, and it is a transcriptional repressor known to bind
GC-rich elements in promoters (Himeda et al., 2008; Parks and
Shenk, 1996; Song et al., 2003),
First, expression of both Sp1 and Maz was conﬁrmed by western
blot in HFKs, and the steady state levels were not altered by E6
(Fig. 2A). Second, when Sp1 was knocked down by two different
siRNAs in E6 expressing HFKs, there was a parallel decrease in hTERT
expression (Table 1). Third, ChIP assay was used to conﬁrm the speciﬁcing their total protein levels: (A) E6 expression did not change total protein levels of
C23 used as a loading control.). (B) ChIP showed Maz was enriched at the hTERT
ed as an internal control. Error bars represent standard deviations of multiple PCRs
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ment of Maz was detected in HFKs (Fig. 2B), but surprisingly this was
reduced to background IgG levels with E6 expression (Fig. 2B).
Conversely, Sp1 was at background levels in HFKs but was increased
three-fold at the promoter of E6 expressing HFKs (Fig. 2B).
The change in promoter occupancy of Maz and Sp1 is not
mediated by changes in the levels of these proteins but facilitated
by some as yet uncharacterized activity of E6.
Knock down of Maz in E6 HFKs further induced histone acetylation at
the hTERT promoter
Although we only detected a background level of Maz at the
hTERT promoter in E6 HFKs, knock down of Maz by siRNA (Fig. 3A)
resulted in increased hTERT mRNA expression (Fig. 3B and Table 1).
However, knock down of Maz in HFKs in the absence of E6 did not
induce hTERT expression (Fig. 3B), indicating that multiple repressors
may be involved in blocking hTERT expression in HFKs.
To determine if Maz regulated hTERT expression through histone
modiﬁcations, as do NFX1-91 and other transcriptional repressors, we
knocked down Maz in E6 HFKs and performed ChIP for acetylated
histone H4 at the hTERT promoter. We detected an increased level of
AcH4 at the hTERT promoter with E6 expression that was augmented
by knock down of Maz (Fig. 3C). Therefore, the removal of Maz from
the hTERT promoter by E6 (Fig. 2B) coupled with further knock downFig. 3. Knock down of Maz in E6 HFKs further induced histone acetylation at the hTERT pro
(C23 used as a loading control.). (B) hTERT mRNA expression was increased by knock do
control. Error bars represent standard deviations of multiple PCRs from two independ
augmentation of AcH4 with Maz knock down in E6 HFKs (Error bars represent standar
Fig. 4. Overexpression of Maz repressed hTERT expression in both 293T and HeLa cells. (A
(GAPDH used as a loading control.). (B) Overexpression of HA-tagged Maz (HA-Maz) in
(C) Overexpression of HA-Maz reduced the hTERT mRNA levels in 293 T and HeLa cells
experiments. 36B4 used as an internal normalizing control.).of Maz by siRNA led to increased hTERT expression and histone
acetylation at the hTERT promoter (Fig. 3B and C).
Overexpression of Maz in cell lines reduced hTERT expression
Because Maz was an important transcriptional repressor of hTERT
in HFKs, we wanted to determine the expression of Maz in different
cell types. We found that Maz was expressed in all cell types tested,
however at varying amounts (Fig. 4A). Considerably more Maz
expression was detected in HFKs that do not express hTERT, and
relatively less in HCT116, HeLa and 293 T cells, which do express
hTERT. As the expression level of Maz was low in HeLa and 293 T
cells, we chose to overexpress HA-tagged Maz in these cell lines
and quantify any change in hTERT expression (either driven by E6
expression in HeLa cells, or not in 293 T cells). HA-tagged Maz (HA-
Maz) was overexpressed in both 293 T cells and HeLa cells (Fig. 4B),
resulting in decreased in hTERT mRNA levels (Fig. 4C). Thus Maz may
be a general repressor of hTERT transcription.
Max and Myc induced hTERT expression in HFKs through enhanced
histone acetylation regulation
Max was the most abundant protein co-puriﬁed with the pYLacO–
hTERTp construct (see Supplementary Table S2). It is a transcriptional
regulator that directly binds DNA and regulates gene expressionmoter: (A) Knock down of Maz by siRNAs was determined by western blot analysis
wn of Maz in E6 HFKs, but not in HFKs alone (36B4 used as an internal normalizing
ent experiments.). (C) ChIP of AcH4 at the hTERT promoter in E6 HFKs showed
d deviations of multiple PCRs from two independent experiments.).
) western blot analysis showed variable expression of Maz in HFKs and cell lines
both 293 T and HeLa cells by western blot analysis (C23 used as a loading control.).
(Error bars represent standard deviations of multiple PCRs from two independent
M. Xu et al. / Virology 446 (2013) 17–24 21through forming either a homodimer with itself or a hetermodimer
with multiple transcriptional activators and repressors (Baudino and
Cleveland, 2001; McDuff et al., 2009) including Myc. Myc/Max
heterodimers have been previously shown to bind to the hTERT
promoter at E-boxes that ﬂank the transcription start site and
upregulate transcription in multiple cell types (Greenberg et al.,
1999; Kyo et al., 2000; Veldman et al., 2003; Xu et al., 2001). Although
Max, but not Myc, was detected by MS analysis in the LacO–LacI
screen, Myc was also not detected in another MS analysis where it was
shown to be a co-purifying protein by other methods (Dominguez-
Sola et al., 2007). Therefore, we tested by western blot for the presence
of both Max and Myc in the anti-Flag IPs from the pYLacO–hTERTp
containing 293 TT cells. As a control a pYLacO–hTERTp plasmid,
containing mutant E-boxes in the hTERT promoter was transfected
into 293 TT cells. Max and Myc were both immunoprecipitated by
LacI-Flag using the wildtype hTERT promoter plasmid, but not with
the E-box mutant promoter (Fig. 5A).
We and others have shown that Myc plays a role in regulating
E6-induced hTERTexpression in HFK cells (Gewin and Galloway, 2001;
Veldman et al., 2003; Xu et al., 2008). Myc is also known to recruit
histone acetyltransferases (HATs) to promoters and increase gene
expression (Frank et al., 2001; Knoepﬂer, 2007). Multiple HATs have
been shown to interact with Myc and regulate Myc-dependent histone
acetylation, including Gcn5 and Tip60 (Frank et al., 2003; Kenneth
et al., 2007). Although the steady state levels of Tip60 are reduced by
high-risk E6 (Fig. 5B) (Jha et al., 2010), like Gcn5, Tip60 was increased
at the hTERT promoter in E6-expressing HFKs (Fig. 5C). This parallels
chromatin immunoprecipitation and expression data of Tip60 at the
HPV promoter in HeLa cells (Jha et al., 2010). Because Myc can recruit
HAT to increase acetylated histones at the hTERT promoter, if Myc
were knocked down, it could decrease histone acetylation. Indeed,
knock down of Myc by two different siRNAs in E6 HFKs resulted in a
decrease in the total amount of acetylated histone H4 (AcH4) (Fig. 5D),
as well as a speciﬁc decrease in the level of AcH4 at the hTERT
promoter (Fig. 5E). Overall this suggests that Myc/Max heterodimers
recruit histone acetylases to E-boxes in the hTERT promoter of E6
expressing HFKs to regulate hTERT transcription.Fig. 5. Myc/Max regulated histone acetylation at the hTERT promoter: (A) Myc and Max co-p
hTERT E-boxes were mutated in 293 TT cells. (B) Tip60 and p53 expression in E6 versus
used as an indicator of E6 expression, and GAPDH used as a loading control.). (C) Increas
assay. (D) Knock down of Myc by siRNA in E6 HFKs reduced total acetylated histone H4 (
(E) Knock down of Myc reduced the relative level of AcH4 by half at the hTERT promoter
standard deviations of multiple PCRs from two independent experiments.).Discussion
hTERT expression is critical for both cell immortalization and
transformation, as well as maintaining a normal stem cell state (Ju
and Rudolph, 2006). Studying mechanisms by which hTERT transcrip-
tion is regulated in both normal and cancer cells are important and
have broad biologic implications. ChIP analysis is a good method to
determine the DNA-protein interactions in vivo. However, it is
dependent on the availability of highly sensitive and speciﬁc
antibodies. In this study, we developed a new system to identify
DNA-interacting proteins in human cells by immunoprecipitating
DNA-protein complexes with a Flag-tagged LacI protein bound to
LacO elements in high copy number plasmids. Proteins in these
complexes can be identiﬁed by MS analysis or interrogated by western
blot assay. Using this LacO–LacI screen, new transcriptional regulators
were identiﬁed, Maz and Foxc1, and the previously known hTERT
regulators Myc and Sp1 were conﬁrmed.
Interestingly, Maz bound to the hTERT promoter in HFK cells, and
E6 expression reduced Maz binding and correspondingly increased
Sp1 binding at the hTERT promoter (Fig. 2B). Knock down of Maz
further induced histone acetylation at the hTERT promoter, as well as
hTERT expression in the presence of E6 (Fig. 3B and C). Although
knock down of Maz alone was not able to induce hTERT expression, it
is likely that Maz adds to the repression of the hTERT gene with
another previously reported repressor NFX1-91. Degradation of NFX1-
91 releases the inhibitory mSin3A-HDAC complex (Gewin et al., 2004;
Xu et al., 2008), which facilitates Myc's recruitment of HATs to the
hTERT promoter. With the removal of Maz at the hTERT promoter by
E6, Sp1 was able to bind and cooperate with Myc to remodel the
chromatin structure and upregulate hTERT transcription. Our data
suggest that both Tip60 and Gcn5 HAT complexes played roles in
regulating E6-induced hTERT transcription, likely due to their shared
binding afﬁnity to TRRAP. This is also supported by a published study
indicating multiple HATs can bind to the same gene promoter and
may regulate expression of the same gene (Wang et al., 2009).
E6 induced the exchange of Maz and Sp1 at the hTERT
promoter without causing any change in their total protein levelsuriﬁed by IP-western blot analysis with wildtype pYLacO-hTERTp but not when the
vector (LXSN) HFKs and HeLa cells by western blot analysis (Loss of p53 expression
ed levels of both Gcn5 and Tip60 bound to the hTERT promoter in E6 HFKs by ChIP
AcH4) protein in E6 HFKs by western blot analysis (C23 used as a loading control.).
by ChIP assay (β-globin used as an internal control for C and E. Error bars represent
M. Xu et al. / Virology 446 (2013) 17–2422(Fig. 2). Casein Kinase 2 (CK2) has been shown to regulate the
phosphorylation of both Maz and Sp1, which affects their DNA
binding activity and transcriptional activities (Armstrong et al.,
1997; Tsutsui et al., 1999), and as such it is interesting to consider
whether E6 may also directly regulate DNA binding activity of Maz
and Sp1, either through protein modiﬁcations or changes in
chromatin structure at the hTERT promoter. Although we did not
detect a signiﬁcant change in Maz protein levels in E6 expressing
HFK cells, a lower Maz expression level was found in HeLa cells
(Fig. 4A), which expresses HPV18 E6. It is possible that other
factors in HeLa cells may affect Maz expression.
We also found that Foxc1 may regulate hTERT transcription
(Table 1), although we were unable to detect Foxc1 direct binding
at the hTERT promoter by ChIP assay (data not shown). This may
be due to the lack of high quality, ChIP-grade, Foxc1 antibodies.
Alternatively, Foxc1 could be indirectly regulating other factors
that regulate hTERT transcription. Previous studies indicated that
Foxc1 is a TGFβ signaling responsive gene in breast cancer cells
(Zhou et al., 2002), so it will be interesting to determine whether
Foxc1 plays a role in TGFβ signaling-regulated hTERT expression in
speciﬁc cell types.
NFX1-91 was found to bind to the hTERT promoter in our
previous studies (Gewin et al., 2004; Xu et al., 2008) but was not
identiﬁed by the MS analysis in this LacO–LacI screen. Like Myc,
NFX1-91 has a short half-life, and as such may be present in low
amounts in the Flag-Lac IPs. Alternatively many proteins do not
ionize well in MS, which may be the case for Myc. Additionally,
there are limitations to the LacO–LacI system design itself. The
LacO–LacI system depends of detectable levels of proteins for MS
analysis or western blot assay, and low abundance or unstable
proteins may be difﬁcult to capture and detect using this screen.
Second, plasmids may not have the same chromatin status as
genomic DNA. Finally, factors that bind to the hTERT promoter
could be different in 293 TT cells versus HFKs or could be detected
only by repeated analyses. It should be noted that other previously
reported hTERT transcriptional regulators, such as Sip1, Menin,
Wt1 and Mzf-2, were not identiﬁed in our MS analysis, however,
their binding sites had been mapped outside the core hTERT
promoter contained in pYLacO–hTERTp (Fujimoto et al., 2000;
Lin and Elledge, 2003; Oh et al., 1999), so this was not unexpected.
It was interesting to ﬁnd that both activators and repressors
bound to the hTERT promoter in the LacO–LacI system, even
though hTERT expression is activated in 293 TT cells. There are
several reasons why this may have occurred. First, there is a
balance of negative and positive factors acting on any given gene,
even those that are actively expressed (Eberharter et al., 2005).
Secondly, plasmids were puriﬁed from unsynchronized cells, so
the combination of both activators and repressors being detected
could be due to cells being collected during different times in the
cell cycle. Third, different chromatin conformations (open or
closed state) may be adopted for each individual plasmid based
on its localization within the nucleus, so different proteins were
recruited by different plasmids.
In summary, a transcription factor binding system developed in
yeast was successfully adapted for use in mammalian cells. With that
system, we identiﬁed new transcriptional regulators of hTERT expres-
sion in HFKs and further deﬁned the concurrent, layered regulation of
a gene critical to HPV-associated cancer development.Material and methods
Cell culture
HeLa cells, 293 T cells, and HCT116 cells were cultured as described
previously (Katzenellenbogen et al., 2010; Xu et al., 2010). Brieﬂy, theywere grown in Dulbecco's modiﬁed Eagle's medium (DME medium,
Life Technologies, Carlsbad, CA) containing 10% fetal bovine serum and
penicillin–streptomycin. 293 TT cells (Buck et al., 2004) were grown in
DME medium containing 10% fetal bovine serum and penicillin–
streptomycin, supplemented with 1% Non-Essential Amino-acids,
1% Glutamax. 293 TT cells were under hygromycin selection to
maintain the expression of T-antigen. Primary HFKs were derived
from neonatal foreskin and grown in Epilife medium supplemented
with 60 μM calcium chloride and human keratinocyte growth supple-
ment (Life Technologies, Carlsbad, CA). Primary HFKs cells stably
expressing HPV16 E6 and control vector LXSN were previously
described (Gewin and Galloway, 2001).
Plasmids and RNAi
The pYLacO plasmid was constructed as follows, the pYseap vector
(Pastrana et al., 2004) was digested with BamHI and ApoI restriction
enzymes to obtain the fragment containing the pUC ori and Blasticidin
R cDNA driven by the SV40 early promoter, which also encodes the
SV40 ori. This fragment was ligated with sequences containing three
copies of LacO that had been digested with BglII and EcoRI restriction
enzymes. The pyLacO–hTERTp plasmid was constructed by releasing
the hTERT promoter (725 to +61 bp) region from pGL3–hTERTp by
digestion with HindIII and NcoI, followed by insertion into the pYLacO
vector. These constructs have been conﬁrmed by sequencing. The
plasmid pLacI-Flag was obtained from Dr. Sue Biggins (Akiyoshi et al.,
2009). Plasmids expressing cDNA of HA-tagged Maz and the control
vector were obtained from Dr. Thomas Shenk. siRNAs used in this
study are listed as follows, Myc siRNA #1: GCUUGUACCUGCAGGAU-
CUTT #2: CGAUGUUGUUUCUGUGGAATT; Sp1 siRNA #1: TTGGGTAA
GTGTGTTGTTTAA #2: TCCCAGAAAGTATATACTGAA; Maz siRNA #1:
CTCGGCTTATATTTCGGACCA #2: TCCTATTTCCCTACCAACCAA; Foxc1
siRNA #1: AACGGGAATAGTAGCTGTCAA #2: CTCCAGTGAACGGGAA-
TAGTA; control siRNA speciﬁc to Luciferase #1: AACGTACGCGGAA-
TACTTCGA #2: AACTTACGCTGAGTACTTCGA.
Transfection and infection
DNA was transiently transfected into 293 T, 293 TT and HeLa
cells using FuGENE6 (Roche, Alameda, CA). siRNA oligos were
transiently transfected into cells using Lipofectamine RNAiMax
reagents (Life Technologies, Carlsbad, CA). Stably expressing of E6
HFK and LXSN HFK cells were obtained by viral transduction as
previously described (Xu et al., 2008).
Western blot and antibodies
Mouse anti-HA (12CA5, Roche, Alameda, CA); Goat anti-Foxc1
(ab5079, Abcam, Cambridge, MA); Mouse-anti-Flag (M2, Sigma,
St. Louis, MO); GAPDH (Abcam, Cambridge, MA); p53Ab6 (Calbio-
chem, LaJolla, CA); and Rabbit-anti-acetyl-Histone H4 (Upstate,
Lake Placid, NY) were used; All other antibodies including Mouse
anti-Myc (C33), Rabbit anti-Maz, Rabbit anti-Sp1, Rabbit-anti-Gcn5
(H-75), Goat anti-Actin (I-19) and Mouse anti-nucleolin were from
Santa Cruz Biotechnology, Santa Cruz, CA.
Quantitative RT-PCR
Total RNAs were extracted from tissue culture plates using
RNeasy mini Kit (Qiagen, Valencia, CA). One microgram of total
RNA was used to synthesize cDNA using Iscript cDNA synthesis kit
(Bio-Rad, Hercules, CA). Real-time quantitative PCR (qPCR) using
power SYBR green (ABI Prism, London, UK) was conducted on an
ABIPrism 9700 and analyzed with SDS 2.2.2 software. hTERT
primers and 36B4 primers (as internal control) used in real-time
PCR were previously described (Xu et al., 2008).
M. Xu et al. / Virology 446 (2013) 17–24 23LacO–LacI immunoprecipitation assay
100 μg Anti-Flag antibody (M2, Sigma, St. Louis, MO) was
crosslinked with prewashed Protein G-Dynabeads using cross-
linking solution (20 mM DMP in 0.2 M triethanolamine, pH8.2) for
40 min. 293 TT cells from 5p150 plates were harvested after 3 h
treatment with 10 mM MG-132 and lysed in NP40 lysis buffer. Cell
lysates were precleared with Protein G-Dynabeads and then
incubated with antibody-conjugated Dynabeads overnight at
4 1C. After overnight incubation with Protein G-Dynabeads, the
beads were rinsed three times with NP40 lysis buffer, washed
three times with NP40 lysis buffer, three times with pre-Elution
buffer (50 mM Tris pH 8.3, 75 mM KCl and 1 mM EGTA), and
eluted in 250 μL Elution buffer (50 mM Tris pH 8.3, 1% Rapigest
and 1 mM EDTA). Immunoprecipitates were separated by SDS-
PAGE and immunoblotted with each speciﬁc antibody.Mass spectrometry analysis
The sample elutions were proteolytically digested by adding
0.25 μg of sequencing-grade trypsin (Promega, Madison, WI) and
incubating them at 37 1C for 18 h. The peptides were then
concentrated using Millipore Zip-Tip u-c18 Pipette tip and eluted
with 10 μL 50% Acetonitrile. The peptides were dried down using a
speed vacuum and resuspended in 7 μL 0.1% Formic acid. The
digested samples were analyzed on the Thermo ﬁnnigan LTQ
mass-spec instrument (Thermo Fisher scientiﬁc, Waltham, MA).
Data were collected in a data-dependent mode, and MS scans were
followed by MS/MS scans of the most abundant ions from the
preceding MS scan. Proteins were identiﬁed by searching against
IPI human database (EBI) using X!Tandem search engine on CPAS
(Computational, Proteomic Analysis System, FHCRC). Protein iden-
tiﬁcation results were ﬁltered by using raw scores greater than
200 for +1 ions, 300 for +2 ions, and 300 for +3 ions; Z scores
greater than or equal to 3; percent ions greater than or equal to
15%; and unique peptides greater than or equal to 2.Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assays for anti-AcH4 and anti-
Myc antibodies were conducted as previously described (Xu et al.,
2008). Chromatin immunoprecipitation assays for Gcn5, Tip60,
Sp1, Maz, and Foxc1 were conducted using protocols from Santa
Cruz Biotechnology, Santa Cruz, CA. Antibodies used for ChIP assay
including Goat anti-Foxc1 (ab5079, Abcam, Cambridge, MA); all
other antibodies including Rabbit anti-Maz (sc-28745x), Goat anti-
Sp1 (sc-59x), Rabbit anti-Gcn5, and Rabbit anti-Tip60 are from
Santa Cruz Biotechnology, Santa Cruz, CA. Rabbit and Goat control
IgG are from Santa Cruz Biotechnology, Santa Cruz, CA. Primers for
both hTERT promoter and control β-globin promoter in ChIP assay
were previously described (Xu et al., 2008). Assays were normal-
ized to control IgG or β-globin based on their consistency across
repeated experiments within a speciﬁc protocol.Funding
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